Global policy and access to new hepatitis C therapies for people who inject drugs

Joseph S. Doyle, Esther J Aspinall, Sharon J. Hutchinson, Brendan Quinn, Charles Gore, Stefan Z. Wiktor, Margaret E. Hellard

Research output: Contribution to journalComment / DebateOtherpeer-review

11 Citations (Scopus)

Abstract

People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed directacting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90% of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risktaking over time. PWID face several barriers to accessing HCV care and treatment that need to be overcome. Testing services need re-orientation toward PWID, individuals need to be informed of their results and provided with direct linkage to ongoing care. Health services need to provide care in the community using simpler, cheaper and more accessible modes of delivery. Healthcare costs and pharmaceutical costs need to be minimised so PWID, who are highly marginalised, can access HCV treatment. Sustained scale-up of treatment for PWID could simultaneously improve individual health and achieve the goal of eliminating HCV transmission among this high-risk and vulnerable group.

Original languageEnglish
Pages (from-to)1064-1071
Number of pages8
JournalInternational Journal of Drug Policy
Volume26
Issue number11
DOIs
Publication statusPublished - 1 Nov 2015

Keywords

  • Hepatitis C virus
  • Global policy
  • Treatment access
  • People who inject drugs

Cite this

Doyle, Joseph S. ; Aspinall, Esther J ; Hutchinson, Sharon J. ; Quinn, Brendan ; Gore, Charles ; Wiktor, Stefan Z. ; Hellard, Margaret E. / Global policy and access to new hepatitis C therapies for people who inject drugs. In: International Journal of Drug Policy. 2015 ; Vol. 26, No. 11. pp. 1064-1071.
@article{91715befa2ee4333ac1f36678372a7a2,
title = "Global policy and access to new hepatitis C therapies for people who inject drugs",
abstract = "People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed directacting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90{\%} of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risktaking over time. PWID face several barriers to accessing HCV care and treatment that need to be overcome. Testing services need re-orientation toward PWID, individuals need to be informed of their results and provided with direct linkage to ongoing care. Health services need to provide care in the community using simpler, cheaper and more accessible modes of delivery. Healthcare costs and pharmaceutical costs need to be minimised so PWID, who are highly marginalised, can access HCV treatment. Sustained scale-up of treatment for PWID could simultaneously improve individual health and achieve the goal of eliminating HCV transmission among this high-risk and vulnerable group.",
keywords = "Hepatitis C virus, Global policy, Treatment access, People who inject drugs",
author = "Doyle, {Joseph S.} and Aspinall, {Esther J} and Hutchinson, {Sharon J.} and Brendan Quinn and Charles Gore and Wiktor, {Stefan Z.} and Hellard, {Margaret E.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.drugpo.2015.05.008",
language = "English",
volume = "26",
pages = "1064--1071",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",
number = "11",

}

Global policy and access to new hepatitis C therapies for people who inject drugs. / Doyle, Joseph S.; Aspinall, Esther J; Hutchinson, Sharon J.; Quinn, Brendan; Gore, Charles; Wiktor, Stefan Z.; Hellard, Margaret E.

In: International Journal of Drug Policy, Vol. 26, No. 11, 01.11.2015, p. 1064-1071.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Global policy and access to new hepatitis C therapies for people who inject drugs

AU - Doyle, Joseph S.

AU - Aspinall, Esther J

AU - Hutchinson, Sharon J.

AU - Quinn, Brendan

AU - Gore, Charles

AU - Wiktor, Stefan Z.

AU - Hellard, Margaret E.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed directacting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90% of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risktaking over time. PWID face several barriers to accessing HCV care and treatment that need to be overcome. Testing services need re-orientation toward PWID, individuals need to be informed of their results and provided with direct linkage to ongoing care. Health services need to provide care in the community using simpler, cheaper and more accessible modes of delivery. Healthcare costs and pharmaceutical costs need to be minimised so PWID, who are highly marginalised, can access HCV treatment. Sustained scale-up of treatment for PWID could simultaneously improve individual health and achieve the goal of eliminating HCV transmission among this high-risk and vulnerable group.

AB - People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed directacting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90% of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risktaking over time. PWID face several barriers to accessing HCV care and treatment that need to be overcome. Testing services need re-orientation toward PWID, individuals need to be informed of their results and provided with direct linkage to ongoing care. Health services need to provide care in the community using simpler, cheaper and more accessible modes of delivery. Healthcare costs and pharmaceutical costs need to be minimised so PWID, who are highly marginalised, can access HCV treatment. Sustained scale-up of treatment for PWID could simultaneously improve individual health and achieve the goal of eliminating HCV transmission among this high-risk and vulnerable group.

KW - Hepatitis C virus

KW - Global policy

KW - Treatment access

KW - People who inject drugs

UR - http://www.scopus.com/inward/record.url?scp=84942194691&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2015.05.008

DO - 10.1016/j.drugpo.2015.05.008

M3 - Comment / Debate

VL - 26

SP - 1064

EP - 1071

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

IS - 11

ER -